Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer.
Adenocarcinoma
/ drug therapy
Aged
Antimetabolites, Antineoplastic
/ therapeutic use
Chemotherapy, Adjuvant
Drug Combinations
Female
Humans
Male
Neoplasm Recurrence, Local
/ drug therapy
Neoplasm Staging
Oxonic Acid
/ therapeutic use
Prognosis
Retrospective Studies
Stomach Neoplasms
/ drug therapy
Survival Rate
Tegafur
/ therapeutic use
Time-to-Treatment
Adjuvant chemotherapy
Gastric cancer
Prognosis
Recurrence
S-1
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
13
02
2019
accepted:
07
05
2019
pubmed:
20
5
2019
medline:
19
11
2019
entrez:
20
5
2019
Statut:
ppublish
Résumé
How the interval between surgery and S-1 adjuvant chemotherapy (ACT), and S-1 relative dose intensity (RDI) affect prognosis in patients with stage II/III gastric cancer who undergo gastrectomy with D2 lymph node dissection followed by S-1 ACT is unclear. We enrolled 95 patients with histopathologically confirmed gastric adenocarcinoma treated with gastrectomy with D2 dissection, followed by S-1 ACT. Per ROC analysis, we used 32 days as the optimal cut-off interval to divide patients into the delayed group (started ACT ≥ 32 days) and the non-delayed group ( < 32 days). Their 5-year overall survival (OS) rates differed significantly (delayed: 54.2%, non-delayed: 85.4%; P < 0.0001). Per ROC analysis of patients without recurrence within 1 year post-surgery, patients were divided into the high RDI (RDI Early initiation and sufficient RDI for S-1 ACT can improve the prognosis of patients with stage II/III gastric cancer.
Sections du résumé
BACKGROUND
BACKGROUND
How the interval between surgery and S-1 adjuvant chemotherapy (ACT), and S-1 relative dose intensity (RDI) affect prognosis in patients with stage II/III gastric cancer who undergo gastrectomy with D2 lymph node dissection followed by S-1 ACT is unclear.
METHODS
METHODS
We enrolled 95 patients with histopathologically confirmed gastric adenocarcinoma treated with gastrectomy with D2 dissection, followed by S-1 ACT.
RESULTS
RESULTS
Per ROC analysis, we used 32 days as the optimal cut-off interval to divide patients into the delayed group (started ACT ≥ 32 days) and the non-delayed group ( < 32 days). Their 5-year overall survival (OS) rates differed significantly (delayed: 54.2%, non-delayed: 85.4%; P < 0.0001). Per ROC analysis of patients without recurrence within 1 year post-surgery, patients were divided into the high RDI (RDI
CONCLUSIONS
CONCLUSIONS
Early initiation and sufficient RDI for S-1 ACT can improve the prognosis of patients with stage II/III gastric cancer.
Identifiants
pubmed: 31104175
doi: 10.1007/s10147-019-01468-0
pii: 10.1007/s10147-019-01468-0
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Drug Combinations
0
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1190-1196Références
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
pubmed: 1688381
Best Pract Res Clin Gastroenterol. 2006;20(4):633-49
pubmed: 16997150
Br J Surg. 2007 Dec;94(12):1468-76
pubmed: 17948223
N Engl J Med. 2007 Nov 1;357(18):1810-20
pubmed: 17978289
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
JAMA. 2011 Jun 8;305(22):2335-42
pubmed: 21642686
Lancet. 2012 Jan 28;379(9813):315-21
pubmed: 22226517
Ann Surg Oncol. 2013 May;20(5):1575-83
pubmed: 23076557
Ann Surg Oncol. 2013 Jun;20(6):2000-6
pubmed: 23242818
Gastric Cancer. 2014;17(3):508-13
pubmed: 23948997
J Clin Oncol. 2014 Mar 10;32(8):735-44
pubmed: 24470007
Ann Surg Oncol. 2016 Feb;23(2):546-51
pubmed: 26442923
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Surgery. 1987 Jul;102(1):71-8
pubmed: 3495896
Cell. 1994 Oct 21;79(2):185-8
pubmed: 7525076
Scand J Plast Reconstr Surg Hand Surg. 1994 Dec;28(4):269-73
pubmed: 7899836